commiss decis propos austria award aid hoffmann la roch compani develop drug orlistat design treatment patholog obes german text authent text eea relev ec commiss european commun regard treati establish european commun subparagraph articl thereof regard agreement establish european econom area articl thereof parti concern opportun submit comment accord abovement articl descript fact anteced letter date octob austria pursuant articl ec treati notifi propos state aid hoffmann la roch hereinaft hlr develop drug orlistat design treatment patholog obes letter date march commiss inform austrian author open procedur provid articl ec treati multin compani hlr began develop anti obes drug orlistat cooper contract hlr chemi linz hereinaft cl chemic compani own austrian state finalis octob novemb produc intermedi compound essenti product drug orlistat contract involv construct linz plant produc hydroxi beta lacton kei intermedi product orlistat implement contract entail phase basic engin work began august signatur contract construct plant start product plan year durat product output intermedi product export switzerland orlistat manufactur state aid propos orlistat project divid part subsidi at million research develop grant at million environment protect aid grant principl feder region local author austria consid aid intens total amount project includ invest research at million commiss decid initi procedur provid articl treati reason previou aid propos notifi octob amount aid present propos present invest aid cl plant locat area elig region aid aid propos withdrawn austria appear inevit commiss decid open procedur mean articl ec treati adopt neg decis regard propos aid research develop commiss express doubt aid conform criteria commun framework state aid research develop research develop activ broad term structur technic approach lack specif technic target mileston incent effect necess aid convincingli demonstr regard aid environment protect technic descript measur envisag gener term detail inform elig cost relationship aid improv environment protect due aid invest aid at million cl retrain cl employe commiss request legisl regulatori inform confirm grant type subsidi open undertak establish austria object discretionari basi final loss make situat cl commiss rais question propos austria grant aid hlr establish hlr linz constitut indirect mean provid state subsidi cl austria observ open articl procedur submit commiss letter regist april meet austrian author commiss place septemb inform receiv letter regist octob novemb member state interest parti inform commiss decis initi proceed invit submit observ public notic june offici journal european commun observ receiv member state parti compani hlr lead intern pharmaceut corpor found compani compris divis pharmaceut vitamin fine chemic diagnost fragranc flavour research develop manufactur market high qualiti product servic field health care pharmaceut divis largest make group sale hlr group employe locat europ north america turnov amount ecu million increas ecu million net incom increas time ecu million ecu million sale region europ north america asia africa australia pacif hlr record innov deriv primarili heavi invest research develop expenditur ecu million amp sale pharmaceut divis amp expenditur pharmaceut sale compani inform take year ecu million bring drug market hlr invest major part profit product sale research develop futur compani compani literatur state hlr address safeti environment issu respons question relat improv product qualiti product consid issu integr part busi activ risk analysi emerg main tool identifi hazard environment protect effort focus pollut prevent total expenditur safeti environment protect ecu million equival sale potenti distort trade member state trend develop anti obes drug treatment obes reduct real perceiv excess bodi weight principl achiev pharmacolog manipul biochem pathwai involv regul bodi weight involv part bodi includ brain fat tissu muscl fibr cell line gut manipul singl pathwai expect field provid suffici clinic benefit give rise commerci feasibl product pathwai studi year includ inhibit gut fat digest enzym term lipas modul digest dietari fat mean stimul oxid fat bodi thermogenesi year rapid increas understand molecular biologi obes driven discoveri gene link obes recent anti obes drug develop summaris sibutramin anti obes treatment knoll pharmaceut compani aris takeov boot pharmaceut basf approv market food drug administr sibutramin work increas level hormon serotonin noradrenalin involv appetit control brain drug work enhanc feel full reduc appetit thought increas energi expenditur sibutramin develop knoll nottingham uk site produc nottingham cramlington compani pursu approv drug europ earli food drug administr approv anti obes drug isomerid dexfenfluramin develop french laboratori servier drug reduc hunger rais level serotonin brain produc interneuron pharmaceut redux uk compani alizym work drug term lipas inhibitor block action fat digest enzym gut reduc intak fat bodi hlr pioneer approach compani file drug applic lipas inhibitor orlistat germani boehring ingelheim danish firm novo nordisk enter multiyear agreement research drug treatment obes focu agreement discoveri drug influenc receptor cell brain fat cell regul food intak energi expenditur number fat cell decreas fat accumul obes peopl ciba geigi basl switzerland synapt pharmaceut paramu jersei usa found neuropeptid npy receptor peptid produc brain import regul appetit potent appetit stimul treatment fight obes target receptor npy synapt ciba geigi engag preclin research small molecul compound specif receptor drug target neuropeptid npy develop collabor neurogen pfizer begun phase clinic trial human unit state custom paid ecu billion weight loss product special diet counter medic result short term effect case redux anti obes drug approv food drug administr expect market analyst gener peak annual sale ecu million enorm market potenti anti obes drug surpris compani work highli competit area target broad rang pharmacolog pathwai develop orlistat develop anti obes drug orlistat usual develop path pharmaceut preclin test compani conduct laboratori anim studi show biolog activ compound target ailment compound evalu safeti phase year clinic trial phase test involv normal healthi volunt focu drug safeti dosag includ studi drug absorpt distribut bodi drug metabol clinic trial phase ii studi volunt patient test drug effect clinic trial phase iii studi patient clinic hospit determin drug efficaci identifi advers reaction clinic trial phase ii iii year drug applic nda compani file nda food drug administr data successfulli demonstr safeti effect approv year approv drug approv market averag compound pass preclin test phase clinic trial final approv preclin test approv excess year cost ecu million drug laboratori market place inform provid austria laboratori work orlistat appar began drug market xenic unit state potent inhibitor intestin lipas block absorpt approxim dietari fat earli appear phase ii clinic trial overweight individu complet phase iii trial due begin appear phase iii trial decemb hlr file drug applic food drug administr compani view xenic import product advertis aim medic profess manag care organis consum analyst forecast peak annual sale reach ecu million proceed open articl procedur mention accord articl procedur commiss invit austrian govern submit observ member state interest parti inform commiss decis initi proceed invit submit observ parti comment receiv austrian govern repli observ submit austrian author argu aid allow summaris aid research develop pharmaceut research specif characterist consider commun framework aid research develop pharmaceut research divid stage stretch year research concept phase preclin test clinic trial name stage subdivid phase involv test signific number person thousand research correspond industri research precompetit develop activ definit state aid guidelin time notif drug orlistat year market research concept phase preclin test stage clinic trial constitut industri research drug year market substanti risk drug pass final stage clinic test stage clinic test regard precompetit develop activ pharmaceut compani carri research anti obes drug procedur orlistat incent effect clear hlr carri product hydoxi beta lacton cl prospect receiv state aid final necess aid austrian author aid high develop cost substanti risk drug approv market innov charact orlistat aid environment protect austrian author measur environment protect implement hlr cl plant standard requir austrian legisl austria provid inform elig cost econom advantag compani aris implement environment measur aid cl personnel retrain subsidi constitut gener measur limit region sector individu compani final indirect aid cl austria consid aid research develop environment protect compat ec treati issu aid intend hlr benefit cl relev ii legal assess compat aid common market articl lai principl provid aid distort threaten distort competit favour undertak product good affect trade member state incompat common market articl set circumst aid allow case articl inapplic ow charact purpos locat aid question articl aid compat common market compat determin context commun singl member state case aid benefit derog point articl area invest realis assist area project import project common european interest aim remedi disturb economi member state intend promot cultur heritag conserv commiss research develop environment measur adopt commun guidelin set criteria assess compat common market state aid area limit discretionari margin point articl commiss compat propos aid assess criteria research develop guidelin environment aid guidelin compat research develop aid common market amp programm research concept phase clinic trial phase iii aid propos at million compani consid total cost develop drug at million aid project state begun propos state aid notifi austrian author octob time phase ii clinic trial demonstr effect orlistat anti obes drug conclud phase iii clinic trial larg number obes individu present phase iii clinic trial complet approv drug sale expect drug develop project success end grant aid hoffmann la roch present time termin amp project constitut priori oper aid compani octob aid notifi phase iii clinic trial begun drug develop project half complet term durat expenditur circumst evid hoffmann la roch began project risk prospect receiv aid commiss call member state demonstr aid incent account oper aid point commun framework research develop case commiss consid austria demonstr aid natur research develop categoris research project definit type research activ fundament research industri research precompetit develop activ meant serv indic close market aid propos defin maximum allow aid intens fundament research industri research qualifi higher level aid precompetit develop activ closer market greater potenti distort competit trade compani amp intens sector carri categori research develop research part normal activ remain competit secur futur competit advantag pharmaceut sector product develop time long categoris research project fundament research industri research precompetit develop activ open wide rang interpret account exist state art technolog technolog trend boundari condit type research develop benefit state fund defin determin amp aid compat common market qualifi fundament research elig fund work link industri commerci object enterpris wide dissemin result research guarante time frame industri sector benefit definit precompetit develop activ encompass research activ elig fund includ creation initi prototyp initi demonstr project pilot project convert industri applic commerci exploit explicitli exclud routin period made product product line manufactur process exist servic oper progress repres improv develop orlistat typic drug develop pharmaceut industri constitut normal oper progress compani time project began consequ strateg busi decis develop anti obes drug develop anti obes drug long object hoffman la roch previous drug develop discontinu varieti reason pharmaceut divis hlr consid preclin research drug develop fundament task consequ split depart la roch annual report compani inform develop function rang clinic trial drug drug regulatori affair reorganis aim streamlin refin busi process pursu process optimis ongo task project notifi phase iii clinic trial compani consid phase part normal busi process research basi commiss agre austria claim work elig fund industri research precompetit develop activ mean state aid guidelin work elig fund appli research develop mean state aid guidelin incent effect aid incent effect propos aid induc compani carri research pursu part normal amp activ examin back time project notifi octob incent effect express research develop guidelin place emphasi ensur aid equival oper aid develop programm anti obes drug orlistat typic pharmaceut sector advanc time notif market prospect perfectli normal pharmaceut compani carri research anti obes drug shown anti obes drug market rapid increas research obes year driven discoveri gene link obes basi commiss agre austrian author argument project ambiti involv expenditur risk normal type drug develop project demand extraordinari effort scope compani normal amp activ conjectur effect grant aid compani octob simpli reduc normal risk commerci failur develop anti obes drug provid state subsidi project carri order compani remain competit gain futur competit advantag incent achiev grant propos aid highli time project notifi commiss octob present time exist commiss consid austria demonstr exist incent effect aid propos aid research develop fulfil criteria set state aid guidelin research develop compat common market compat aid environment protect measur hlr offer implement addit measur austrian author consider level environment protect requir austria standard promot hlr mandatori environment standard applic chemic plant project linz legal basi feder law appli austria offer hlr legisl requir made assumpt aid promis austrian author grant environment measur consid addit measur hlr implement state aid seri environment measur concern measur reduc risk environment accid measur prevent water pollut measur combat air pollut specif measur aid propos figur at million gt tabl gt measur elig aid high oper save involv implement addit measur austrian author submit detail descript standard legal requir invest need achiev standard requir natur addit measur invest relat addit measur aid element express monetari term percentag elig cost measur reduc risk accid seri measur present austria reduct risk environment accid open procedur commiss state assess invest environment aspect strict approach order prevent firm receiv aid suppos environment expenditur serv financ invest carri event commiss continu plant inevit built highest level safeti market difficult accept state aid grant firm reach level final commiss ad aid measur improv protect worker health improv firm effici reduc cost declar compat common market measur event contrari measur austrian author notifi environment aid alleg justif seri measur reduc releas environ pollut substanc eman normal product activ target reduc risk explos releas harm substanc case oper plant malfunct main purpos measur prevent catastroph occurr minimis harm human employe adjac resid primarili aim reduc environment damag propos measur prevail mandatori standard austria aid necess justifi prevent accid constitut oblig compani case accid bear liabil commiss view state aid grant cover compani oblig austria provid justif consid measur primarili environment elig benefit state aid suppos safeti technolog construct chemic plant mention commiss view highest level safeti implement interest compani public opinion firm fulli expect carri risk analysi implement safeti measur order prevent accid safeti prevent damag kei concern chemic compani accid involv high liabil loss public imag reduct sale high prioriti safeti confirm hlr compani literatur foreword safeti environ protect roch group report chairman board director state continu studi damag scenario logic led chang attitud wait passiv damag occur player shift attent measur design prevent damag risk analysi emerg main tool identifi hazard perform process plant risk analysi enabl chemist engin assess impact process deviat reduc risk accept level suitabl technic organis personnel measur chairman ad safeti environment protect sole oblig govern public integr part busi activ fact safeti matter vital concern chemic industri gener hlr confirm report state hlr present data satisfi demand specialist readership reach wider audienc employe custom sharehold give background inform broader pictur make easier assess roch data safeti measur aim reduc risk accid kei part busi activ hlr necess aid favour measur demonstr aid safeti measur foreseen tabl consid gener invest mean commun guidelin state aid environment protect exclud scope basi commiss consid aid propos plan safeti measur compat common market measur combat water air pollut measur aim prevent water pollut intend significantli reduc emiss danub measur enabl emiss solvent residu substanc phenylethylamin stop permit exist environment regul addit level organ halogen compound aox wastewat reduc measur combat air pollut claim reduc emiss atmospher hydrocarbon heat transfer oil danger dust solvent emiss permit exist environment regul measur reduc uncontrol releas gase environ exist standard exceed aid invest significantli higher level environment protect attain requir mandatori standard authoris maximum gross elig cost level aid grant order exce mandatori standard proport environment improv achiev extra invest achiev improv due account cost save advantag obtain investor back invest element deduct nomin extra invest cost achiev elig cost mutati mutandi oper cost ad invest order obtain elig cost take account arithmet error commit austrian author subtract oper save aid amount extra invest amount aid allow abovement guidelin figur million at gt tabl gt grant aid at addit measur prevent water air pollut conform commun guidelin state aid environment protect compat common market accord derog articl ec treati aid personnel train chemi linz open proceed commiss request austrian author confirm train aid firm chemi linz cl gener measur measur base order aid gener industri train measur implement labour market aid act part iv legal basi extens modifi articl read conjunct articl point labour market servic aim measur train peopl previous firm labour market servic bodi charg realloc unemploi peopl labour market object rais level individu qualif increas individu profession mobil measur austrian author restrict region sector firm discretionari decis bodi order train aid criteria account assess applic risk job loss compani unemploi person hire compani train train obtain firm long term commit compani train programm subsidi grant object automat criteria consid state aid mean articl ec treati reliev firm financi cost aris normal econom activ articl act access austria finland sweden european union decis efta surveil author date access pursuant articl eea agreement fall articl ec treati result access access remain valid respect articl ec treati commiss decid pursuant articl ec treati major modif place legal basi train aid scheme question notifi efta surveil author esa pursuant articl protocol surveil court agreement austrian author compli notif oblig scheme consid aid exist aid illeg put forc esa commiss state view conform state aid rule assess commiss limit individu aid at million cl retrain employe enabl oper chemic plant product hydroxi beta lacton prejudic posit commiss scheme amount aid small at million ecu compar cost train programm at million year cover peopl aid intens gross train obtain individu aid firm mean specif firm oper aid consid measur favour worker compani benefit indirectli clear ow financi econom difficulti suffer cl potenti risk job loss employe compani benefit train aid chanc find qualifi job case lose present job posit commiss measur promot train acquisit skill express guidelin aid employ state measur fall scope articl ec treati commiss sympathet consider consider commiss consid propos grant plan individu train aid compat common market accord derog provid articl ec treati indirect restructur aid chemi linz decis initi proceed case commiss consid find aid measur compat treati rule aid environ research altern question ask regard aid chemi linz compani financi difficulti notifi aid amp environment protect concern commiss found part compat merit common market part incompat incompat aid grant hlr constitut indirect aid cl examin aspect longer relev adopt decis articl research develop aid at million austria plan grant hoffmann la roch develop anti obes drug orlistat compat common market mean articl propos aid paid articl aid at million austria propos grant hoffmann la roch addit measur reduc risk accid oper plant hydroxi beta lacton linz compat common market mean articl propos aid paid articl environment aid at million hoffmann la roch addit measur prevent water pollut combat air pollut oper plant mention articl compat common market mean articl articl individu aid at million grant chemi linz retrain employe enabl oper chemic plant product hydroxi beta lacton illeg ground scheme grant notifi efta surveil author requir articl act access austria finland sweden european union prejudic posit commiss scheme individu aid chemi linz consid compat common market mean articl articl republ austria inform commiss measur compli decis month date notif articl decis address republ austria brussel commiss karel van miert member commiss oj oj oj oj oj oj